These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

297 related articles for article (PubMed ID: 36210250)

  • 1. Modelling optimal vaccination strategies against COVID-19 in a context of Gamma variant predominance in Brazil.
    Ferreira LS; de Almeida GB; Borges ME; Simon LM; Poloni S; Bagattini ÂM; da Rosa MQM; Diniz Filho JAF; Kuchenbecker RS; Camey SA; Kraenkel RA; Coutinho RM; Toscano CM
    Vaccine; 2022 Nov; 40(46):6616-6624. PubMed ID: 36210250
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine in children aged 6-17 years: a preliminary report of COV006, a phase 2 single-blind, randomised, controlled trial.
    Li G; Cappuccini F; Marchevsky NG; Aley PK; Aley R; Anslow R; Bibi S; Cathie K; Clutterbuck E; Faust SN; Feng S; Heath PT; Kerridge S; Lelliott A; Mujadidi Y; Ng KF; Rhead S; Roberts H; Robinson H; Roderick MR; Singh N; Smith D; Snape MD; Song R; Tang K; Yao A; Liu X; Lambe T; Pollard AJ;
    Lancet; 2022 Jun; 399(10342):2212-2225. PubMed ID: 35691324
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relationship between SARS-CoV-2 vaccination and cases, program breakthrough cases, and deaths in Dois Vizinhos, Paraná, Brazil.
    Vasconcelos MW; de Barros FRO; Pilonetto JC; Rosa SGB; Gonçalves S; Kuhn BC; De Assis Leite DC; Perseguini JMKC; Gabiatti NC; Wendt SN; Ghisi NC
    J Med Virol; 2023 Jun; 95(6):e28882. PubMed ID: 37350013
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The hindrances to perform the COVID-19 vaccination in Brazil.
    Boschiero MN; Palamim CVC; Marson FAL
    Hum Vaccin Immunother; 2021 Nov; 17(11):3989-4004. PubMed ID: 34353218
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vaccine effectiveness of ChAdOx1 nCoV-19 against COVID-19 in a socially vulnerable community in Rio de Janeiro, Brazil: a test-negative design study.
    Ranzani OT; Silva AAB; Peres IT; Antunes BBP; Gonzaga-da-Silva TW; Soranz DR; Cerbino-Neto J; Hamacher S; Bozza FA
    Clin Microbiol Infect; 2022 May; 28(5):736.e1-736.e4. PubMed ID: 35150884
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of COVID-19 vaccination strategies with a delayed second dose.
    Moghadas SM; Vilches TN; Zhang K; Nourbakhsh S; Sah P; Fitzpatrick MC; Galvani AP
    PLoS Biol; 2021 Apr; 19(4):e3001211. PubMed ID: 33882066
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effectiveness of homologous and heterologous booster doses for an inactivated SARS-CoV-2 vaccine: a large-scale prospective cohort study.
    Jara A; Undurraga EA; Zubizarreta JR; González C; Pizarro A; Acevedo J; Leo K; Paredes F; Bralic T; Vergara V; Mosso M; Leon F; Parot I; Leighton P; Suárez P; Rios JC; García-Escorza H; Araos R
    Lancet Glob Health; 2022 Jun; 10(6):e798-e806. PubMed ID: 35472300
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative effectiveness and durability of COVID-19 vaccination against death and severe disease in an ongoing nationwide mass vaccination campaign.
    Lytras T; Kontopidou F; Lambrou A; Tsiodras S
    J Med Virol; 2022 Oct; 94(10):5044-5050. PubMed ID: 35701379
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluating the Impact of SARS-CoV-2 Variants on the COVID-19 Epidemic and Social Restoration in the United States: A Mathematical Modelling Study.
    Li R; Li Y; Zou Z; Liu Y; Li X; Zhuang G; Shen M; Zhang L
    Front Public Health; 2021; 9():801763. PubMed ID: 35083192
    [No Abstract]   [Full Text] [Related]  

  • 10. Expert review on global real-world vaccine effectiveness against SARS-CoV-2.
    Chuenkitmongkol S; Solante R; Burhan E; Chariyalertsak S; Chiu NC; Do-Van D; Husin M; Hwang KP; Kiertiburanakul S; Kulkarni PS; Lee PI; Lobo RC; Nghia CH; Ong-Lim A; Sivasampu S; Suah JL; Tok PSK; Thwaites G;
    Expert Rev Vaccines; 2022 Sep; 21(9):1255-1268. PubMed ID: 35748494
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modelling the impact of delaying vaccination against SARS-CoV-2 assuming unlimited vaccine supply.
    Amaku M; Covas DT; Coutinho FAB; Azevedo RS; Massad E
    Theor Biol Med Model; 2021 Jul; 18(1):14. PubMed ID: 34325717
    [TBL] [Abstract][Full Text] [Related]  

  • 12. COVID-19 vaccine waning and effectiveness and side-effects of boosters: a prospective community study from the ZOE COVID Study.
    Menni C; May A; Polidori L; Louca P; Wolf J; Capdevila J; Hu C; Ourselin S; Steves CJ; Valdes AM; Spector TD
    Lancet Infect Dis; 2022 Jul; 22(7):1002-1010. PubMed ID: 35405090
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Humoral immune response after different SARS-CoV-2 vaccination regimens.
    Rose R; Neumann F; Grobe O; Lorentz T; Fickenscher H; Krumbholz A
    BMC Med; 2022 Jan; 20(1):31. PubMed ID: 35057798
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness of a Third Dose of mRNA Vaccines Against COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance - VISION Network, 10 States, August 2021-January 2022.
    Thompson MG; Natarajan K; Irving SA; Rowley EA; Griggs EP; Gaglani M; Klein NP; Grannis SJ; DeSilva MB; Stenehjem E; Reese SE; Dickerson M; Naleway AL; Han J; Konatham D; McEvoy C; Rao S; Dixon BE; Dascomb K; Lewis N; Levy ME; Patel P; Liao IC; Kharbanda AB; Barron MA; Fadel WF; Grisel N; Goddard K; Yang DH; Wondimu MH; Murthy K; Valvi NR; Arndorfer J; Fireman B; Dunne MM; Embi P; Azziz-Baumgartner E; Zerbo O; Bozio CH; Reynolds S; Ferdinands J; Williams J; Link-Gelles R; Schrag SJ; Verani JR; Ball S; Ong TC
    MMWR Morb Mortal Wkly Rep; 2022 Jan; 71(4):139-145. PubMed ID: 35085224
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quantifying the effect of delaying the second COVID-19 vaccine dose in England: a mathematical modelling study.
    Imai N; Rawson T; Knock ES; Sonabend R; Elmaci Y; Perez-Guzman PN; Whittles LK; Kanapram DT; Gaythorpe KAM; Hinsley W; Djaafara BA; Wang H; Fraser K; FitzJohn RG; Hogan AB; Doohan P; Ghani AC; Ferguson NM; Baguelin M; Cori A
    Lancet Public Health; 2023 Mar; 8(3):e174-e183. PubMed ID: 36774945
    [TBL] [Abstract][Full Text] [Related]  

  • 16. COVID-19 pandemic dynamics in India, the SARS-CoV-2 Delta variant, and implications for vaccination.
    Yang W; Shaman J
    medRxiv; 2021 Nov; ():. PubMed ID: 34845460
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Age and product dependent vaccine effectiveness against SARS-CoV-2 infection and hospitalisation among adults in Norway: a national cohort study, July-November 2021.
    Starrfelt J; Danielsen AS; Buanes EA; Juvet LK; Lyngstad TM; Rø GØI; Veneti L; Watle SV; Meijerink H
    BMC Med; 2022 Sep; 20(1):278. PubMed ID: 36050718
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness of the BNT162b2 (Pfizer-BioNTech) and the ChAdOx1 nCoV-19 (Oxford-AstraZeneca) vaccines for reducing susceptibility to infection with the Delta variant (B.1.617.2) of SARS-CoV-2.
    Pattni K; Hungerford D; Adams S; Buchan I; Cheyne CP; García-Fiñana M; Hall I; Hughes DM; Overton CE; Zhang X; Sharkey KJ
    BMC Infect Dis; 2022 Mar; 22(1):270. PubMed ID: 35307024
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Avoidable COVID-19-related deaths and hospitalizations in Brazil, 2020-2023.
    Kupek E
    Vaccine; 2024 May; 42(15):3437-3444. PubMed ID: 38631953
    [TBL] [Abstract][Full Text] [Related]  

  • 20. COVID-19 vaccination during pregnancy: coverage and safety.
    Blakeway H; Prasad S; Kalafat E; Heath PT; Ladhani SN; Le Doare K; Magee LA; O'Brien P; Rezvani A; von Dadelszen P; Khalil A
    Am J Obstet Gynecol; 2022 Feb; 226(2):236.e1-236.e14. PubMed ID: 34389291
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.